Clinical Trial Update: Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating sorafenib in combination with irinotecan for metastatic colorectal cancer, including patients with K-RAS mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Camptosar (irinotecan)
• Nexavar (Sorafenib)

Snippet

Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle | Conditions: Metastatic Colorectal Cancer | Phase 1, Phase 2 | Status: COMPLETED